Abstract
The role of rapidly growing mycobacteria in the pathogenesis of pulmonary disease is being increasingly recognized; however, the clinical significance of these mycobacteria in patients with underlying malignancy has not been well studied. Over a 6-year period, 37 cancer patients with rapidly growing mycobacteria isolated from respiratory specimens were identified at our center.Mycobacterium chelonae group was isolated in 24 cases andMycobacterium fortuitum in 13 cases. Of the 24 cases with cultures yieldingMycobacterium chelonae group, eight met the study criteria for infection and were determined to be clinically significant, whereas only one of theMycobacterium fortuitum isolates was determined to represent infection. An average of two antimicrobial agents were used for treatment, most commonly clarithromycin, ciprofloxacin, and trimethoprim/sulfamethoxazole. Although the isolation of rapidly growing mycobacteria represents colonization in most cases, these bacteria, especially theMycobacterium chelonae group, may cause pulmonary disease in cancer patients. The clinical and radiological findings are usually non-specific in this population, and patients with respiratory cultures yielding rapidly growing mycobacteria should be assessed carefully to distinguish infection from colonization. Effective therapy can be provided with oral regimens that include at least two antibiotics to which the organism is susceptible.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Goslee S, Wolinsky E: Water as a source of potentially pathogenic mycobacteria. American Review of Respiratory Disease (1976) 113:287–292
Wolinsky E, Rynearson TK: Mycobacteria in soil and their relation to disease-associated strains. American Review of Respiratory Disease (1968) 97:1032–1037
Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS: Spectrum of disease due to rapidly growing mycobacteria. Reviews of Infectious Diseases (1983) 5:657–679
Jackson PG, Keen H, Noble CJ, Simmons NA: Injection abscesses due toMycobacterium chelonei occurring in a diabetic patient. Tubercle (1981) 62:277–279
Hoffman PC, Fraser DW, Robicsek F, O'Bar PR, Mauncy CU: Two outbreaks of sternal wound infections due to organisms of theMycobacterium fortuitum complex. Journal of Infectious Diseases (1981) 143:533–542
Wallace RJ Jr, Steele LC, Labidi A, Silcox VA: Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammoplasty despite case clustering in Texas and other southern coastal states. Journal of Infectious Diseases (1989) 160:281–288
Dugel PU, Holland GN, Brown HH, Pettit TH, Hofbauer JD, Simons KB, Ullman H, Bath PE, Foos RY:Mycobacterium fortuitum keratitis. American Journal of Ophthalmology (1988) 105:661–669
Meisler DM, Friedlaender MH, Okumoto M:Mycobacterium chelonei keratitis. American Journal of Ophthalmology (1982) 94:398–401
Merlin TL, Tzamaloukas AH:Mycobacterium chelonae peritonitis associated with continuous ambulatory peritoneal dialysis. American Journal of Clinical Pathology (1989) 91:717–720
Band JD, Ward JI, Fraser DW, Peterson NJ, Silcox VA, Good RC, Ostroy PR, Kennedy J: Peritonitis due to aMycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis. Journal of Infectious Diseases (1982) 145:9–17
Repath F, Seabury JH, Sanders CV, Domer J: Prosthetic valve endocarditis due toMycobacterium chelonei. Southern Medical Journal (1976) 69:1244–1246
Laskovvski LF, Marr JJ, Spernoga JF, Frank NJ, Barner HB, Kaiser G, Tyras DH: Fastidious mycobacteria grown from porcine prosthetic-heart-valve cultures. New England Journal of Medicine (1977) 297:101–102
Brannan DP, DuBois RE, Ramirez MJ, Ravry MJR, Harrison EO: Cefoxitin therapy forMycobacterium fortuitum bacteremia with associated granulomatous hepatitis. Southern Medical Journal (1984) 77:381–384
Sopko JA, Fieselmann J, Kasik JE: Pulmonary disease due toMycobacterium chelonei subspeciesabscessus: a report of four cases. Tubercle (1980) 61:165–169
Zina AM, Depaoli M, Bossano AF: Cutaneous-mucous infection with lymphadenopathy caused byMycobacterium chelonei. Dermatologica (1980) 160:376–379
Righter J, Hart GD, Howes M:Mycobacterium chelonei: report of a case of septicemia and review of the literature. Diagnostic Microbiology and Infectious Disease (1983) 1:323–329
Raad II, Vartivarian S, Khan A, Bodey G: Catheter-related infections caused by theMycobacterium fortuitum complex: 15 cases and review. Reviews of Infectious Diseases (1991) 13:1120–1125
Hoy JF, Rolston KVI, Hopfer L, Bodey GP:Mycobacterium fortuitum bacteremia in patients with cancer and long-term venous catheters. American Journal of Medicine (1987) 83:213–217
Ingram CW, Tanner DC, Durack DT, Kernodle GW Jr, Corey GR: Disseminated infection with rapidly growing mycobacteria. Clinical Infectious Diseases (1993) 16:463–471
Nelson BR, Rapini RP, Wallace RJ Jr, Tschen JA: DisseminatedMycobacterium chelonae ssp.abscessus in an immunocompetent host and with a known portal of entry. Journal of the American Academy of Dermatology (1989) 20:909–912
Burns DN, Rohatgi PK, Rosenthal R, Seiler M, Gordin FM: DisseminatedMycobacterium fortuitum successfully treated with combination therapy including ciprofloxacin. American Review of Respiratory Disease (1990) 142:468–470
McWhinney PHM, Yates M, Prentice HG, Thrussell M, Gillespie SH, Kibbler CC: Infection caused byMycobacterium chelonae: a diagnostic and therapeutic problem in the neutropenic patient. Clinical Infectious Diseases (1992) 14:1208–1212
Rolston KVI, Jones PG, Fainstein V, Bodey GP: Pulmonary disease caused by rapidly growing mycobacteria in patients with cancer. Chest (1985) 4:503–506
Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C: Antimicrobial susceptibility of five subgroups ofMycobacterium fortuitum andMycobacterium chelonae. Antimicrobial Agents and Chemotherapy (1985) 28:807–811
Wallace RJ Jr, Bedsole G, Sumter G, Sanders CV, Steele LC, Brown BA, Smith J, Graham DR: Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrobial Agents and Chemotherapy (1990) 34:65–70
Wallace RJ Jr, Brown BA, Onyi GO: Susceptibilities ofMycobacterium fortuitum biovar.fortuitum and the two subgroups ofMycobacterium chelonae to imipenim, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrobial Agents and Chemotherapy (1991) 35:773–775
Silcox VA, Good RC, Floyd MM: Identification of clinically significantMycobacterium fortuitum complex isolates. Journal of Clinical Microbiology (1981) 14:686–691
Swensen SJ, Hartman TE, Williams DE: Computed tomographic diagnosis ofMycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest (1994) 105:49–52
Verghese G, Shepherd R, Watt P, Bruce JH: Fatal infection withMycobacterium fortuitum associated with oesophageal achalasia. Thorax (1988) 43:151–152
Dreisin RB, Scoggin C, Davidson PT: The pathogenicity ofMycobacterium fortuitum andMycobacterium chelonei in man: a report of seven cases. Tubercle (1976) 57:49–57
Boxerbaum B: Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. Journal of Pediatrics (1980) 96:689–691
Awe RJ, Gangadharam PR, Jenkins DE: Clinical significance ofMycobacterium fortuitum infections in pulmonary disease. American Review of Respiratory Disease (1973) 108:1230–1234
Tsukamura M, Nakamura E, Kurita I, Nakamura T: Isolation ofMycobacterium chelonei subspecies chelonei (Mycobacterium borstelense) from pulmonary lesions of 9 patients. American Review of Respiratory Disease (1973) 108:683–685
Howard RS II, Woodring JH, Vandiviere HM, Dillon ML:Mycobacterium fortuitum pulmonary infection complicating achalasia. Southern Medical Journal (1991) 84:1391–1393
Griffith DE, Girard WM, Wallace RJ Jr: Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. American Review of Respiratory Disease (1993) 147:1271–1278
Wallace RJ Jr: The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria,M. fortuitum andM. chelonae. Clinics in Chest Medicine (1989) 10:419–429
Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA: Clinical trial of clarithromycin for cutaneous (disseminated) infection due toMycobacterium chelonae. Annals of Internal Medicine (1993) 119:482–486
Tebas P, Sultan F, Wallace RJ Jr, Fraser V: Rapid development of resistance to clarithryomycin following monotherapy for disseminatedMycobacterium chelonae infection in a heart transplant patient. Clinical Infectious Diseases (1995) 20:443–444
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jacobson, K., Garcia, R., Libshitz, H. et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur. J. Clin. Microbiol. Infect. Dis. 17, 615–621 (1998). https://doi.org/10.1007/BF01708343
Issue Date:
DOI: https://doi.org/10.1007/BF01708343